Poly (ADP-ribose) polymerase (PARP) inhibitors are used as maintenance therapy after completion of platinum-based chemotherapy in ovarian cancer. However, acquired or de novo resistance to PARP inhibitors is frequent and limits their application.
Researchers from Novacyte Therapeutics Co. Ltd. presented preclinical data for NC-18, a novel HER2-targeting antibody drug conjugate (ADC) being developed for the treatment of HER2-positive/expressing advanced solid tumors.
Cyclins and cyclin-dependent kinases (CDKs) regulate the activity of E2F and Rb to drive cell cycle progression. Disrupting this interaction has shown lethality in cancer cells harboring alterations that lead to higher expression of E2F1.
Claudin 18.2 (CLDN18.2) is a member of the claudin family and is overexpressed in gastric, gastroesophageal junction and pancreatic cancer, among others. Researchers from Elevation Oncology Inc. recently presented preclinical efficacy data on the combination of EO-3021, an antibody-drug conjugate (ADC) targeting CLDN18.2, with VEGFR-2 or PD-1 inhibitors in models of gastric adenocarcinoma.
Endocrine therapy against the estrogen receptor (ER) is widely used for the treatment of ER+ breast cancer. Selective estrogen receptor degraders (SERDs) compete directly with estrogen for ER binding and create an unstable protein complex that leads to proteasome-mediated ER protein degradation.
Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s Office of Autoimmune Disease Research and Office of Research in Women’s Health earlier this month. Cancer, that line of reasoning goes, arises when the immune system is not good enough at recognizing harmful autoantigens. Autoimmunity arises when it is hypervigilant, mistaking harmless autoantigens for problematic ones and going on the attack.
Beigene Ltd. struck a global licensing deal with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. worth up to $1.5 billion for its phase I selective methionine adenosyltransferase 2A (MAT2A) inhibitor, SYH-2039, which is being explored for solid tumors.
The EMA’s Committee for Medicinal Products for Human Use recommended 17 drugs for approval at its December meeting, bringing the total for 2024 to 114. That is up from the 77 drugs recommended for approval in 2023, of which 39 were novel.
Mixed results for three of Bicycle Therapeutics plc’s zelenectide pevedotin development programs preceded a strong drop in the company’s stock. Bicycle shares (NASDAQ:BCYC) dropped 31.3% on Dec. 13 to close at $13.81 each, the stock’s lowest price in the past 12 months.
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has big plans for the combo therapy.
RSS
